Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study explores safer cancer surgery for liver patients

NCT ID NCT07368309

Knowledge-focused Sponsor: Renmin Hospital of Wuhan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study examined how to best manage early-stage upper gastrointestinal cancer in patients who also have liver cirrhosis and enlarged veins in the esophagus (varices). Researchers compared outcomes of a keyhole-like endoscopic surgery (ESD) between 206 patients with and without cirrhosis. The goal was to find safer and more effective screening and treatment approaches for this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
endoscopic submucosal dissection (ESD)
What this could lead to
If successful, this could help doctors choose safer and more effective treatment strategies for early-stage upper GI cancer in patients with cirrhosis and varices.
What could go wrong
This is a retrospective study, meaning it looks back at past data, so it cannot prove cause and effect. Results may not apply to all patients, and the small size limits reliability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

206 people

The number who actually took part.

Started

Aug 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Consecutive patients who underwent ESD for early-stage upper gastrointestinal cancer between January 2018 and April 2023 were enrolled. See the previous entry for specific eligibility criteria

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The cirrhosis group: * Age \>18 years; * A clinical diagnosis of liver cirrhosis * Endoscopically confirmed EGV. The noncirrhosis group: * Age \> 18 years * With early-stage upper gastrointestinal cancer but without cirrhosis Exclusion Criteria: * Concomitant end-stage disease of major organs (e.g., active malignancy, heart failure, respiratory failure) or an American Society of Anesthesiologists (ASA) physical status classification ≥ III * Previous surgery for cirrhosis, EGV, or other upper gastrointestinal lesions * Incomplete clinical records.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cirrhosis of liver digestive system neoplasm esophageal varices Fibrosis microinvasive gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis Early-stage upper gastrointestinal cancer Esophagogastric varices

Contacts and locations

Locations

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.